ReviewAlzheimer's research & therapy2020
Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg.
Review in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- Global and Medial Temporal MRI Morphometry in Alzheimer's Disease and Cognitively Normal Adults: A Retrospective Association Study.Diagnostics (Basel, Switzerland) · 2026Article
- Alterations in neuroinflammatory and neurodegenerative biomarkers among long-term residents of a critically polluted area: a cross-sectional comparative study.Scientific reports · 2025Article
- Association between chronic PMBMC public health · 2025Article
- Blood-derived APLP1Science advances · 2025Article
- Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases.Journal of nanobiotechnology · 2024Review
- Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case-control study of patients with bipolar disorder and healthy control individuals.International journal of bipolar disorders · 2024Article
- Role of Specific Autoantibodies in Neurodegenerative Diseases: Pathogenic Antibodies or Promising Biomarkers for Diagnosis.Antibodies (Basel, Switzerland) · 2023Review
- Clinical biomarkers for Lewy body diseases.Cell & bioscience · 2023Review
- Data Mining of Microarray Datasets in Translational Neuroscience.Brain sciences · 2023Review
- Research progress on the role of extracellular vesicles in neurodegenerative diseases.Translational neurodegeneration · 2023Review
- Future Perspectives of Oxytosis/Ferroptosis Research in Neurodegeneration Diseases.Cellular and molecular neurobiology · 2023Review
- Molecular Biomarkers of Neuronal Injury in Epilepsy Shared with Neurodegenerative Diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases.Translational neurodegeneration · 2023Review
- Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit.Alzheimer's research & therapy · 2023Article
- Diagnostic challenges for dementia in Australia: are blood-based biomarkers the solution?Internal medicine journal · 2022Article
- Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy.Alzheimer's research & therapy · 2022Article
- Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders.Biomolecules · 2022Article
- Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer's Disease.Biomedicines · 2022Article
- Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status.Biomedicines · 2022Review
- Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications.Cells · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until relatively recently, a diagnosis of probable Alzheimer's disease (AD) and other neurodegenerative disorders was principally based on clinical presentation, with post-mortem examination remaining a gold standard for disease confirmation. This is in sharp contrast to other areas of medicine, where fluid biomarkers, such as troponin levels in myocardial infarction, form an integral part of the diagnostic and treatment criteria. There is a pressing need for such quantifiable and easily accessible tools in neurodegenerative diseases.In this paper, based on lectures given at the 2019 Biomarkers in Neurodegenerative Diseases Course, we provide an overview of a range of cerebrospinal fluid (CSF) and blood biomarkers in neurodegenerative disorders, including the 'core' AD biomarkers amyloid β (Aβ) and tau, as well as other disease-specific and general markers of neuroaxonal injury. We then highlight the main challenges in the field, and how those could be overcome with the aid of new methodological advances, such as assay automation, mass spectrometry and ultrasensitive immunoassays.As we hopefully move towards an era of disease-modifying treatments, reliable biomarkers will be essential to increase diagnostic accuracy, allow for earlier diagnosis, better participant selection and disease activity and treatment effect monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.